Stock Groups

Capri Holdings, Boston Scientific, Brinker and others


Take a look at the top companies that made headlines long before the bell rang.

Capri Holdings (CPRI) – The company behind Michael Kors and other luxury brands reported better-than-expected earnings for its latest quarter and raised its profit forecast as demand for handbags and apparel remained strong. Capri’s adjusted earnings for the quarter were $2.22 per share, which beat the consensus estimate of $1.69. The stock also jumped 10.8% on the premarket.

Boston Scientific (BSX) – The medical device maker’s stock slumped 4.4% in premarket trading after the company reported a weaker-than-expected outlook. Boston Scientific earned 45 cents per share in adjusted earnings, beating the 44 cent consensus estimate.

Waste Management (WM) – Waste Management shares added 2.4% in the premarket, after announcing a planned dividend increase and projecting full-year revenue above current Wall Street forecasts. Waste Management posted adjusted earnings in the most recent quarter of $1.26 per shares, which is consistent with analyst estimates.

Brinker International (EAT) – The parent of Chili’s and other restaurant chains saw its shares surge 8% in the premarket after reporting a bottom-line beat for its latest quarter. Brinker’s adjusted earnings were 71 cents per shared, which was 20 cents higher than estimates. However, revenue was slightly less than forecasts.

D.R. Horton (DHI) – The home builder’s stock rallied 4% in premarket trading after a top and bottom-line beat amid robust housing market conditions. D.R. Horton reported a $3.17 share in its most recent quarter, against a $2.79 consensus estimate.

Alphabet (GOOGL) – Alphabet surged 10.6% in the premarket following a blowout earnings report as well as the announcement of a 20-for-1 stock split. Alphabet’s fourth-quarter earnings were $30.69 per share, which was higher than the consensus estimate of $27.34. Revenue also exceeded expectations as digital advertising sales surged.

General Motors (GM) – GM came in 16 cents above estimates with adjusted quarterly earnings of $1.35 per share, although the automaker’s revenue came in short of Wall Street projections. GM released a positive 2022 forecast, and stated that it will accelerate efforts to manufacture and market electric cars. In premarket actions, GM increased 3.3%.

Starbucks (SBUX) – Starbucks fell 8 cents short of estimates, reporting an adjusted quarterly profit of 72 cents per share, though revenue came in above estimates. According to Starbucks, higher labor and commodity costs have weighed on its bottom line. The situation is expected to continue for the next few months. Starbucks saw a 2.8% drop in premarket sales.

PayPal (PYPL) – PayPal plunged 16.8% in the premarket after it missed bottom-line forecasts and issued a weaker-than-expected current-quarter outlook. PayPal fell by one penny from consensus estimates with adjusted quarterly earnings at $1.11 per shares, but the company’s revenue exceeded expectations. The former parent is taking a toll on PayPal’s results eBayContinuous transition to new methods of payment Rival BlockIn the aftermath of PayPal’s announcement, (SQ), formerly Square, plunged 6.9%

Advanced Micro Devices (AMD) – AMD beat estimates by 16 cents with an adjusted quarterly profit of 92 cents per share, while the chip maker’s revenue also topped forecasts. AMD forecasts better than expected full-year revenues due to continued high demand for its data centre chips. AMD stock rose 12.4% during premarket trading

Match Group (MTCH) – Match Group is under pressure after the operator of Tinder and other dating services issued a softer-than-expected full-year revenue forecast on the expectation that Covid-19 will continue to hinder dating activity. Match Group’s quarterly adjusted earnings were 63cs, surpassing estimates by 10 cents. Premarket activity saw Match Group fall 3.7%

Gilead Sciences (GILD) – The drug maker’s shares fell 3% in the premarket after it reported a lower-than-expected quarterly profit amid declining sales of its Covid-19 treatment remdesivir. Gilead also agreed to $1.25 Billion to compensate. GlaxoSmithKline(GSK), to resolve a patent dispute regarding HIV treatment.